Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-12-11 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
独立董事候选人声明（JIANGNAN CAI蔡江南）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of a company, detailing compliance with various legal and regulatory requirements for serving as an independent director. It includes statements about qualifications, independence, and adherence to relevant laws and regulations. There is no financial data, no discussion of company performance, no voting results, no management changes, and no report or presentation content. This type of document is related to board/management information, specifically concerning the appointment or status of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is about 5,099 characters, which is consistent with a detailed declaration rather than a brief announcement or a full report.
2022-12-11 Chinese
关于召开2022年第三次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2022 third extraordinary general meeting of shareholders for Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, agenda items, voting procedures, and attachments such as proxy forms and shareholder registration forms. The content focuses on the announcement and procedural details of the shareholders' meeting rather than the meeting materials or results. There is no financial data, audit information, or earnings results presented. The document is not a report itself but a formal notification to shareholders about the meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length (7268 characters) supports it being a full notice rather than a brief announcement of a report publication.
2022-12-11 Chinese
关于董事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement from 贝达药业股份有限公司 regarding the re-election of the company's board of directors. It details the nomination and qualifications of candidates for the new board, including both independent and non-independent directors. The document references compliance with company law and stock exchange regulations, and includes detailed biographies of the director candidates. There is no financial data, earnings information, or report publication mentioned. The content is focused on board/management changes and governance matters. Therefore, the document fits the category of Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2022-12-11 Chinese
独立董事提名人声明（黄欣琪）
Board/Management Information Classification · 100% confidence The document is a public statement from the board of directors nominating an individual (黄欣琪女士) as an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with relevant laws and regulations, and a summary table of the nominee's current directorships and executive roles. There are no financial statements, earnings data, or report attachments. The content focuses on board/management information, specifically the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length (6230 characters) supports it being a full statement rather than a brief announcement or certification.
2022-12-11 Chinese
独立董事候选人声明（黄欣琪）
Board/Management Information Classification · 100% confidence The document is a detailed declaration by an independent director candidate of a company, confirming compliance with various legal and regulatory requirements for serving as an independent director. It includes statements about qualifications, independence, and absence of conflicts of interest, as well as a summary table of the candidate's current directorships. There are no financial statements, earnings data, or report summaries. The content is focused on board/management information, specifically about a director candidate's qualifications and declarations. This fits the category of Board/Management Information (MANG). The document length is sufficient and contains substantive content related to management rather than a brief announcement or regulatory filing.
2022-12-11 Chinese
独立董事关于第三届董事会第三十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various proposals discussed at the 38th meeting of the third board of directors of Betta Pharmaceuticals Co., Ltd. It includes opinions on investment proposals, board member nominations, independent director remuneration, and use of idle raised funds. The content focuses on governance matters, board nominations, and related party transactions, with no financial statements or earnings data. The document is a formal opinion related to board and shareholder meeting agenda items, not a full report or announcement of financial results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related governance opinions.
2022-12-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.